



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

HL-60 + PMA Cell Lysate: sc-24705

BACKGROUND

Santa Cruz Biotechnology offers a variety of whole cell lysates for use in combination with our antibodies as Western Blotting controls. HL-60 Whole Cell Lysate is derived from the HL-60 cell line using a procedure that ensures protein integrity and lot-to-lot reproducibility. All lysates are tested by Western Blotting to assure that each one contains the expected concentration and assortment of proteins. Numerous antibodies directed against a wide array of mammalian proteins are used to test each lysate.

HL-60 is a promyelocytic cell line derived by S.J. Collins, et al. Peripheral blood leukocytes were obtained by leukopheresis from a 36 year old Caucasian female with acute promyelocytic leukemia. HL-60 cells spontaneously differentiate, and differentiation can be stimulated by butyrate, hypoxanthine, phorbol myristic acid (PMA, TPA), dimethylsulfoxide (DMSO, 1-1.5%), actinomycin D or retinoic acid. The cells exhibit phagocytic activity and responsiveness to chemotactic stimuli. The line is positive for Myc oncogene expression.

REFERENCES

- Collins, S.J., et al. 1977. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. *Nature* 270: 347-349.
- Collins, S.J., et al. 1978. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. *Proc. Natl. Acad. Sci. USA* 75: 2458-2462.
- Gallagher, R., et al. 1979. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. *Blood* 54: 713-733.

SOURCE

HL-60 + PMA Cell Lysate is derived from the HL-60 cell line and induced with PMA.

Organism: *Homo sapiens* (human)
Organ: Peripheral blood
Disease: Acute promyelocytic leukemia
Growth Properties: Suspension

PRODUCT

Western blotting (WB)-ready (denatured and reduced protein) endogenous whole cell lysates are ready to load for SDS-PAGE, and are provided in a single vial. Each vial contains 500 µg protein in 200 µl [2.5 µg/µl], containing 2X Electrophoresis Sample Buffer (sc-24945).

APPLICATIONS

Western blotting (WB)-ready endogenous mammalian protein whole cell lysates (for SDS-PAGE) are provided at a final concentration of 500 µg protein in 200 µl [2.5 µg/µl]. Thaw/heat at 95° C for 3-5 minutes. For endogenous controls, load up to 20 µl (50 µg) per lane (15 well (8.0 cm x 8.0 cm) gel).


STORAGE

Store at -20° C, avoid repeated freeze/thaw cycles. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


PREPARATION METHOD

Mammalian cells are cultured *in vitro* under an appropriate buffered media condition to either an optimal suspension cell density, or optimal adherent cell sub-confluency. Cells are then harvested from cell culture media for protein extraction using the RIPA Lysis Buffer System (sc-24948). Bicinchoninic acid (BCA) protein assay calibration determines the protein concentration for each preparation. Western blotting (WB)-ready endogenous whole cell lysates contain 500 µg protein in 200 µl [2.5 µg/µl] at 1:1 with 2X Electrophoresis Sample Buffer (sc-24945).

DATA



Western blot analysis of Integrin α X expression in uninduced control (A) and PMA-induced (B) HL-60 whole cell lysates.



Western blot analysis of TDAG8 expression in mouse thymus (A) and mouse spleen (B) extracts and CCRF-CEM (C), PMA-treated HL-60 (D), CD3 (21-L5)-treated Jurkat (E) and untreated Jurkat (F) whole cell lysates.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.